CClinicalTrials.gg
CompletedNCT02289729ADEQUAUpdated Jan 30, 2019Results posted

Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease

An observational study in Parkinson's Disease, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-01-30.

Sponsored by AbbVie · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
62
Ages
18 Years to 99 Years
Sex
All
01

Study summary

Patient reported outcomes (PRO) have become an important endpoint assessed in clinical trials. It is important to understand the relationship between medication and patients' symptomatology, quality of life and well-being. We predict levodopa/carbidopa intestinal gel (LCIG; Duodopa) will significantly improve quality of life and emotional well-being compared to baseline in patients with advance Parkinson disease (APD) not well controlled with conventional treatment.

02

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Duodopa
  • Advanced Parkinson's Disease
  • Levodopa/Carbidopa intestinal gel
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's enrollment of 62 is below the median of 96 across 1,057 observational studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

AbbVie is the lead sponsor of 953 studies on the registry; 136 are open to participants now.

Of its 350 completed or terminated interventional studies of FDA-regulated products, 210 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Advanced Parkinson's Disease patients

Inclusion criteria

  • Patients with advanced levodopa-responsive Parkinson's disease, with at least, 2 hours "off" time or 2 hours of dyskinesia based on clinician's/investigator's medical judgment
  • Patients with advanced Parkinson's disease with severe motor fluctuations and dyskinesia when combination of conventional PD treatments was unable to satisfactory control symptoms.
  • Patients with advanced Parkinson's disease who meet the criteria for use of Levodopa/Carbidopa Intestinal Gel (LCIG) established in the summary of product characteristics, Spanish Neurology Society (SEN) guidelines, local/regional directories (CCAA) or site's protocols for use of LCIG in common clinical practice.
  • The decision to treat with LCIG is made by the physician prior to any decision to approach the patient to participate in this study.
  • Patients with a cognitive level enough to complete the questionnaires, confirmed by a Mini-mental state examination (MMSE) score of at least 26 points, according to the recommendation of the Movement Disorder Society (MDS) task force on dementia in Parkinson's Disease (PD)

Exclusion criteria

Exclusion Criteria:

  • LCIG's contraindications included in the Summary of Product Characteristics (product label)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
62 participants (actual)

Groups and cohorts

  • All Participants

    Levodopa/carbidopa intestinal gel (LCIG) prescribed in the usual manner, in accordance with the terms of the local marketing authorization, for participants with advanced Parkinson's disease with motor fluctuation not well responding to conventional therapies.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Parkinson's Disease Questionnaire-39 Item (PDQ-39) Global Score at Month 6

    The PDQ-39 contains 39 items: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (score 0 to 4 on a Likert scale). The global score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

    Time frame: Baseline, Month 6 (±15 days)

  2. Change From Baseline in PDQ-39 Mobility Domain Score at Month 6

    The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The mobility domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

    Time frame: Baseline, Month 6 (±15 days)

  3. Change From Baseline in PDQ-39 Activities of Daily Living Domain Score at Month 6

    The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The activities of daily living domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

    Time frame: Baseline, Month 6 (±15 days)

  4. Change From Baseline in PDQ-39 Emotional Well-Being Domain Score at Month 6

    The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The emotional well-being domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

    Time frame: Baseline, Month 6 (±15 days)

  5. Change From Baseline in PDQ-39 Stigma Domain Score at Month 6

    The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The stigma domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

    Time frame: Baseline, Month 6 (±15 days)

  6. Change From Baseline in PDQ-39 Social Support Domain Score at Month 6

    The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The social support domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

    Time frame: Baseline, Month 6 (±15 days)

  7. Change From Baseline in PDQ-39 Cognition Domain Score at Month 6

    The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The cognition domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

    Time frame: Baseline, Month 6 (±15 days)

  8. Change From Baseline in PDQ-39 Communication Domain Score at Month 6

    The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The communication domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

    Time frame: Baseline, Month 6 (±15 days)

  9. Change From Baseline in PDQ-39 Bodily Discomfort Domain Score at Month 6

    The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The bodily discomfort domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

    Time frame: Baseline, Month 6 (±15 days)

Secondary outcomes

  1. Change From Baseline in Unified Parkinson's Disease Rating Scale Part III (UPDRS-III): Motor Examination at Month 6

    The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS-III was used in ON state. The motor examination contains 27 items. Each item is scored in a Likert scale from 0 to 4. The UPDRS-III score was calculated summing the score of each item, ranging from 0 to 108, with higher score indicating more impairment.

    Time frame: Baseline, Month 6 (±15 days)

  2. Change From Baseline in the Non-Motor Symptom Scale (NMSS) Global Score at Month 6

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The global score was calculated summing the score of each item (severity x frequency), ranging from 0 to 360, with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline, Month 6 (±15 days)

  3. Change From Baseline in NMSS Cardiovascular Domain Score at Month 6

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The cardiovascular domain score ranges from 0 to 24 with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline, Month 6 (±15 days)

  4. Change From Baseline in NMSS Sleep/Fatigue Domain Score at Month 6

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The sleep/fatigue domain score ranges from 0 to 48 with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline, Month 6 (±15 days)

  5. Change From Baseline in NMSS Mood/Cognition Domain Score at Month 6

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The mood/cognition domain score ranges from 0 to 72 with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline, Month 6 (±15 days)

  6. Change From Baseline in NMSS Perceptual Problems/Hallucinations Domain Score at Month 6

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The perceptual problems/hallucinations domain score ranges from 0 to 36 with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline, Month 6 (±15 days)

  7. Change From Baseline in NMSS Attention/Memory Domain Score at Month 6

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The attention/memory domain score ranges from 0 to 36 with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline, Month 6 (±15 days)

  8. Change From Baseline in NMSS Gastrointestinal Tract Domain Score at Month 6

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The gastrointestinal tract domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline, Month 6 (±15 days)

  9. Change From Baseline in NMSS Urinary Domain Score at Month 6

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The urinary domain score ranges from 0 to 36 with a lower score indicating fewer symptoms.A negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline, Month 6 (±15 days)

  10. Change From Baseline in NMSS Sexual Function Domain Score at Month 6

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The sexual function domain score ranges from 0 to 24 with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline, Month 6 (±15 days)

  11. Change From Baseline in NMSS Miscellaneous Domain Score at Month 6

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The miscellaneous domain score ranges from 0 to 48 with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline, Month 6 (±15 days)

  12. Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Mean Global Score at Month 6

    The Norris/Bond-Lader VAS measures emotional well-being status with a 16-item visual analogue mood rating scale. The VAS consisted of 16 visual analogue items each representing opposite extremes of mood, with the following labels at each end: alert/drowsy, calm/excited, strong/weak, muzzy/clear-headed, well-coordinated/clumsy, lethargic/energetic, contented/dreamy, incompetent/proficient, happy/sad, antagonistic/amicable, interested/bored, withdrawn/gregarious. These scales loaded on 3 domains (alert, strong, clear-headed, well-coordinated, energetic, quick-witted, attentive, proficient, interested); (contented, tranquil, happy, amicable, gregarious); (calm, relaxed). For each individual scale, a line was drawn between each mood state and its opposite and participants rated their current mood by placing a vertical mark on the line. Scores (global, and for each domain) ranged from 0 to 100, with lower scores indicating more positive mood.

    Time frame: Baseline, Month 6 (±15 days)

  13. Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Alertness/Sedation Sub-Scale Score at Month 6

    The Norris/Bond-Lader VAS measures emotional well-being status with a 16-item visual analogue mood rating scale. The VAS consisted of 16 visual analogue items each representing opposite extremes of mood, with the following labels at each end: alert/drowsy, calm/excited, strong/weak, muzzy/clear-headed, well-coordinated/clumsy, lethargic/energetic, contented/dreamy, incompetent/proficient, happy/sad, antagonistic/amicable, interested/bored, withdrawn/gregarious. These scales loaded on 3 domains (alert, strong, clear-headed, well-coordinated, energetic, quick-witted, attentive, proficient, interested); (contented, tranquil, happy, amicable, gregarious); (calm, relaxed). For each individual scale, a line was drawn between each mood state and its opposite and participants rated their current mood by placing a vertical mark on the line. Scores (global, and for each domain) ranged from 0 to 100, with lower scores indicating more positive mood.

    Time frame: Baseline, Month 6 (±15 days)

  14. Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Contented/Discontented Sub-Scale Score at Month 6

    The Norris/Bond-Lader VAS measures emotional well-being status with a 16-item visual analogue mood rating scale. The VAS consisted of 16 visual analogue items each representing opposite extremes of mood, with the following labels at each end: alert/drowsy, calm/excited, strong/weak, muzzy/clear-headed, well-coordinated/clumsy, lethargic/energetic, contented/dreamy, incompetent/proficient, happy/sad, antagonistic/amicable, interested/bored, withdrawn/gregarious. These scales loaded on 3 domains (alert, strong, clear-headed, well-coordinated, energetic, quick-witted, attentive, proficient, interested); (contented, tranquil, happy, amicable, gregarious); (calm, relaxed). For each individual scale, a line was drawn between each mood state and its opposite and participants rated their current mood by placing a vertical mark on the line. Scores (global, and for each domain) ranged from 0 to 100, with lower scores indicating more positive mood.

    Time frame: Baseline, Month 6 (±15 days)

  15. Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Calmness/Relaxation Sub-Scale Score at Month 6

    The Norris/Bond-Lader VAS measures emotional well-being status with a 16-item visual analogue mood rating scale. The VAS consisted of 16 visual analogue items each representing opposite extremes of mood, with the following labels at each end: alert/drowsy, calm/excited, strong/weak, muzzy/clear-headed, well-coordinated/clumsy, lethargic/energetic, contented/dreamy, incompetent/proficient, happy/sad, antagonistic/amicable, interested/bored, withdrawn/gregarious. These scales loaded on 3 domains (alert, strong, clear-headed, well-coordinated, energetic, quick-witted, attentive, proficient, interested); (contented, tranquil, happy, amicable, gregarious); (calm, relaxed). For each individual scale, a line was drawn between each mood state and its opposite and participants rated their current mood by placing a vertical mark on the line. Scores (global, and for each domain) ranged from 0 to 100, with lower scores indicating more positive mood.

    Time frame: Baseline, Month 6 (±15 days)

  16. Change From Baseline in Parkinson Fatigue Scale (PFS-16) at Month 6

    The PFS-16 comprises 16 items with five polytomous response categories (strongly disagree, disagree, do not agree or disagree, agree, and strongly agree). Responses were scored from 0 (strongly disagree) to 4 (strongly agree), yielding a summed total score ranging from 0 (no fatigue) to 64 (most severe fatigue). The cut-point of ≥ 3.30 was used to identified those perceiving fatigue to be a problem.

    Time frame: Baseline, Month 6 (±15 days)

  17. Change From Baseline in the Score of the Apathy Scale (AS) to Month 6

    The AS is an inventory of 14 questions that assess cognitive and behavioral symptoms of emotional apathy. Each is rated from 0 to 3 on a Likert scale. The total scores for AS ranges from 0 (no apathy) to 42 (most apathetic). AS scores ≥ 14 were considered apathetic.

    Time frame: Baseline, Month 6 (±15 days)

  18. Change From Baseline in Beck Depression Inventory, Second Edition (BDI-II) at Month 6

    The BDI-II is a 21-item self-report multiple-choice inventory. Items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63. Raw scores from 0-13 indicates minimal depression, 14-19 indicates mild depression, 20-28 indicates moderate depression, and 29-63 indicates severe depression.

    Time frame: Baseline, Month 6 (±15 days)

  19. Change From Baseline in Beck Anxiety Inventory (BAI) at Month 6

    The BAI is a 21-item self-report multiple-choice inventory. Items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63. Raw scores from 0-7 indicates minimal anxiety, 8-15 indicates mild anxiety, 16-25 indicates moderate anxiety, and 25-63 indicates severe anxiety.

    Time frame: Baseline, Month 6 (±15 days)

  20. Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Composite Score at Month 6

    The SATMED-Q is a 17-item questionnaire. Items are grouped in 6 domains: undesirable side effects (items 1-3), treatment effectiveness (items 4-6), convenience of use (items 7-9), impact on daily living activities (items 10-12), medical care (items 13-14), and global satisfaction (items 15-17). Items are rated on a 5-point scale ranging from 0 to 4. Summing up the direct scores of the items yields a total composite score ranging between 0 and 68, which was transformed to a minimum of 0 (most satisfied) and a maximum of 100 (least satisfied).

    Time frame: Baseline, Month 6 (±15 days)

  21. Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Undesirable Side Effects at Month 6

    The SATMED-Q is a 17-item questionnaire. Items are grouped in 6 domains: undesirable side effects (items 1-3), treatment effectiveness (items 4-6), convenience of use (items 7-9), impact on daily living activities (items 10-12), medical care (items 13-14), and global satisfaction (items 15-17). Items are rated on a 4-point scale ranging from 0 to 4. Summing up the direct scores of the items yields a total undesirable side effects score ranging between 0 and 12, which was transformed to a minimum of 0 (most satisfied) and a maximum of 100 (least satisfied).

    Time frame: Baseline, Month 6 (±15 days)

  22. Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Treatment Effectiveness at Month 6

    The SATMED-Q is a 17-item questionnaire. Items are grouped in 6 domains: undesirable side effects (items 1-3), treatment effectiveness (items 4-6), convenience of use (items 7-9), impact on daily living activities (items 10-12), medical care (items 13-14), and global satisfaction (items 15-17). Items are rated on a 4-point scale ranging from 0 to 4. Summing up the direct scores of the items yields a total treatment effectiveness score ranging between 0 and 12, which was transformed to a minimum of 0 (most satisfied) and a maximum of 100 (least satisfied).

    Time frame: Baseline, Month 6 (±15 days)

  23. Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Convenience of Use at Month 6

    The SATMED-Q is a 17-item questionnaire. Items are grouped in 6 domains: undesirable side effects (items 1-3), treatment effectiveness (items 4-6), convenience of use (items 7-9), impact on daily living activities (items 10-12), medical care (items 13-14), and global satisfaction (items 15-17). Items are rated on a 4-point scale ranging from 0 to 4. Summing up the direct scores of the items yields a total convenience of use score ranging between 0 and 12, which was transformed to a minimum of 0 (most satisfied) and a maximum of 100 (least satisfied).

    Time frame: Baseline, Month 6 (±15 days)

  24. Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Impact on Daily Living Activities at Month 6

    The SATMED-Q is a 17-item questionnaire. Items are grouped in 6 domains: undesirable side effects (items 1-3), treatment effectiveness (items 4-6), convenience of use (items 7-9), impact on daily living activities (items 10-12), medical care (items 13-14), and global satisfaction (items 15-17). Items are rated on a 4-point scale ranging from 0 to 4. Summing up the direct scores of the items yields a total impact on daily living activities score ranging between 0 and 12, which was transformed to a minimum of 0 (most satisfied) and a maximum of 100 (least satisfied).

    Time frame: Baseline, Month 6 (±15 days)

  25. Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Medical Care at Month 6

    The SATMED-Q is a 17-item questionnaire. Items are grouped in 6 domains: undesirable side effects (items 1-3), treatment effectiveness (items 4-6), convenience of use (items 7-9), impact on daily living activities (items 10-12), medical care (items 13-14), and global satisfaction (items 15-17). Items are rated on a 4-point scale ranging from 0 to 4. Summing up the direct scores of the items yields a total medical care score ranging between 0 and 8, which was transformed to a minimum of 0 (most satisfied) and a maximum of 100 (least satisfied).

    Time frame: Baseline, Month 6 (±15 days)

  26. Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Global Satisfaction at Month 6

    The SATMED-Q is a 17-item questionnaire. Items are grouped in 6 domains: undesirable side effects (items 1-3), treatment effectiveness (items 4-6), convenience of use (items 7-9), impact on daily living activities (items 10-12), medical care (items 13-14), and global satisfaction (items 15-17). Items are rated on a 4-point scale ranging from 0 to 4. Summing up the direct scores of the items yields a total global satisfaction score ranging between 0 and 12, which was transformed to a minimum of 0 (most satisfied) and a maximum of 100 (least satisfied).

    Time frame: Baseline, Month 6 (±15 days)

  27. Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Composite Score at Month 6

    The SQLC is designed to both qualitatively and quantitatively evaluate the impact of a patient's disease on the caregiver's quality of life. The SQLC questionnaire consists of 16 questions that evaluate 3 domains: professional activities (questions 1-4), social and leisure activities (questions 5-9), and caregiving responsibilities (questions 10-16). Composite scores range from 0 to 149, with higher scores indicating higher quality of life.

    Time frame: Baseline, Month 6 (±15 days)

  28. Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Professional Activities at Month 6

    The SQLC is designed to both qualitatively and quantitatively evaluate the impact of a patient's disease on the caregiver's quality of life. The SQLC questionnaire consists of 16 questions that evaluate 3 domains: professional activities (questions 1-4), social and leisure activities (questions 5-9), and caregiving responsibilities (questions 10-16). Professional activities scores range from 0 to 38, with higher scores indicating higher quality of life.

    Time frame: Baseline, Month 6 (±15 days)

  29. Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Social and Leisure Activities at Month 6

    The SQLC is designed to both qualitatively and quantitatively evaluate the impact of a patient's disease on the caregiver's quality of life. The SQLC questionnaire consists of 16 questions that evaluate 3 domains: professional activities (questions 1-4), social and leisure activities (questions 5-9), and caregiving responsibilities (questions 10-16). Social and leisure activities scores range from 0 to 58, with higher scores indicating higher quality of life.

    Time frame: Baseline, Month 6 (±15 days)

  30. Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Caregiving Responsibilities at Month 6

    The SQLC is designed to both qualitatively and quantitatively evaluate the impact of a patient's disease on the caregiver's quality of life. The SQLC questionnaire consists of 16 questions that evaluate 3 domains: professional activities (questions 1-4), social and leisure activities (questions 5-9), and caregiving responsibilities (questions 10-16). Caregiving responsibilities scores range from 0 to 53, with higher scores indicating higher quality of life.

    Time frame: Baseline, Month 6 (±15 days)

  31. Change From Baseline in Zarit Burden Interview (ZBI) at Month 6

    The ZBI is a 22-item questionnaire in which caregivers must evaluate the level of agreement on a 5-point Likert scale from 0 to 4. The total score is obtained by the sum of the scores of the items. This total score represents a level of caregiver burden, with a range of 0 indicating no burden to 88 indicating completely overloaded.

    Time frame: Baseline, Month 6 (±15 days)

  32. Change From Baseline in the Caregiver Stress Index (CSI) at Month 6

    The CSI is a 13-item questionnaire based on identified common stressors. Answers are in yes/no format. Scoring is 1 point for each "yes" and 0 for each "no". The total score is obtained by the sum of the scores of the items. Minimum score is 0 (no stress) and maximum score is 13 (most stress). A score ≥ 7 indicates a high level of stress.

    Time frame: Baseline, Month 6 (±15 days)

  33. Change From Baseline in Goldberg Anxiety and Depression Score (GADS): Depression Sub-Scale for Caregivers at Month 6

    The GADS is an 18-item self-report symptom inventory made up of two sub-scales, one for the detection of anxiety and another one for the detection of depression. Both sub-scales are composed of 9 questions. Answers are in yes/no format. Scoring is 1 point for each "yes" and 0 for each "no", with a total sub-scale score of 0 (no anxiety/depression) to 9 (worst anxiety/depression). In the Spanish validation of GADS, the cutoff point to consider probable anxiety disorder is 4 and 2 for probable depression.

    Time frame: Baseline, Month 6 (±15 days)

  34. Change From Baseline in Goldberg Anxiety and Depression Score (GADS): Anxiety Sub-Scale for Caregivers at Month 6

    The GADS is an 18-item self-report symptom inventory made up of two sub-scales, one for the detection of anxiety and another one for the detection of depression. Both sub-scales are composed of 9 questions. Answers are in yes/no format. Scoring is 1 point for each "yes" and 0 for each "no", with a total sub-scale score of 0 (no anxiety/depression) to 9 (worst anxiety/depression). In the Spanish validation of GADS, the cutoff point to consider probable anxiety disorder is 4 and 2 for probable depression.

    Time frame: Baseline, Month 6 (±15 days)

  35. Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) at Month 6

    Absenteeism, presented as the mean percentage of work time missed due to caregiving (as reported on the WPAI), and calculated as: 100\*number of hours of work missed due to caregiving / (number of hours of work missed due to caregiving + number of hours worked). WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.

    Time frame: Baseline, Month 6 (±15 days)

  36. Change From Baseline in WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Caregiving (Presenteeism)

    Presenteeism (the extent to which caregiving decreased productivity) is presented as the mean percentage of impairment while working due to caregiving, and calculated as: 100\*scale value of question 5 on the WPAI (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.

    Time frame: Baseline, Month 6 (±15 days)

  37. Change From Baseline in WPAI Questionnaire: Mean Percentage of Overall Work Productivity Impairment (OWPI) Due to Caregiving

    The mean percentage of OWPI due to caregiving (based on the WPAI questionnaire) is presented, calculated as: Absenteeism (%) + extent to which caregiving decreased productivity (%)\* \[number of hours worked / (number of hours of work missed due to caregiving + number of hours worked)\]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.

    Time frame: Baseline, Month 6 (±15 days)

  38. Change From Baseline in WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Caregiving

    Activity impairment due to caregiving (the extent to which caregiving affected the ability to perform usual daily activities) is presented as the mean percentage of activity impairment, calculated as 100\*scale value of WPAI question 6 (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity/activity and 100% representing complete impact on productivity/activity.

    Time frame: Baseline, Month 6 (±15 days)

  39. Correlation Between Participants' Quality of Life (PDQ-39) and Different Questionnaires at Baseline

    Spearman correlation statistics were calculated for the quality of life of the participants (Global PDQ-39, see Outcome Measure 1) and the following scales: UPDRS-III (see Outcome Measure 10), UPDRS-IV (see description below), NMSS (see Outcome Measure 11), BAI (see Outcome Measure 28), BDI-III (see Outcome Measure 27), AS (see Outcome Measure 26), PFS (see Outcome Measure 25), Norris Bond-Lader (NBL) Alertness-Sedation (A-S; see Outcome Measure 22), NBL Contented-Discontented (C-D; see Outcome Measure 23), NBL Calm-Relaxed (C-R; see Outcome Measure 24), ZBI (see Outcome Measure 40), GADS-Anxiety (see Outcome Measure 43), and GADS-Depression (see Outcome Measure 42). The UPDRS-IV contains 11 items, each scored in a Likert scale from 0 (normal) to 4 (severe); or a 2-point scale (yes/no format), with 1 point for "yes" and 0 for "no." The global score was calculated summing the score of each item, ranging from 0 to 23, where higher scores are associated with more disability.

    Time frame: Baseline

  40. Correlation Between Participants' Quality of Life (PDQ-39) and Different Questionnaires at Month 6

    Spearman correlation statistics were calculated for the quality of life of the participants (Global PDQ-39, see Outcome Measure 1) and the following scales: UPDRS-III (see Outcome Measure 10), UPDRS-IV (see description below), NMSS (see Outcome Measure 11), BAI (see Outcome Measure 28), BDI-III (see Outcome Measure 27), AS (see Outcome Measure 26), PFS (see Outcome Measure 25), Norris Bond-Lader (NBL) Alertness-Sedation (A-S; see Outcome Measure 22), NBL Contented-Discontented (C-D; see Outcome Measure 23), NBL Calm-Relaxed (C-R; see Outcome Measure 24), ZBI (see Outcome Measure 40), GADS-Anxiety (see Outcome Measure 43), and GADS-Depression (see Outcome Measure 42). The UPDRS-IV contains 11 items, each scored in a Likert scale from 0 (normal) to 4 (severe); or a 2-point scale (yes/no format), with 1 point for "yes" and 0 for "no." The global score was calculated summing the score of each item, ranging from 0 to 23, where higher scores are associated with more disability.

    Time frame: Month 6 (±15 days)

  41. Correlation Between Caregivers' Quality of Life (SQLC) and Different Questionnaires at Baseline

    Spearman correlation statistics were calculated for the quality of life of the caregivers (Global SQLC, see Outcome Measure ) and the following scales: ZBI (see Outcome Measure 40), GADS-Anxiety (see Outcome Measure 43), and GADS-Depression (see Outcome Measure 42), NBL A-S (see Outcome Measure 22), NBL C-D (see Outcome Measure 23), NBL C-R (see Outcome Measure 24), Global PDQ-39 (see Outcome Measure 1), UPDRS-III (see Outcome Measure 10), UPDRS-IV (see description below), and Global NMSS (see Outcome Measure 11). The UPDRS-IV contains 11 items, each scored in a Likert scale from 0 (normal) to 4 (severe); or a 2-point scale (yes/no format), with 1 point for "yes" and 0 for "no." The global score was calculated summing the score of each item, ranging from 0 to 23, where higher scores are associated with more disability.

    Time frame: Baseline

  42. Correlation Between Caregivers' Quality of Life (SQLC) and Different Questionnaires at Month 6

    Spearman correlation statistics were calculated for the quality of life of the caregivers (Global SQLC, see Outcome Measure ) and the following scales: ZBI (see Outcome Measure 40), GADS-Anxiety (see Outcome Measure 43), and GADS-Depression (see Outcome Measure 42), NBL A-S (see Outcome Measure 22), NBL C-D (see Outcome Measure 23), NBL C-R (see Outcome Measure 24), Global PDQ-39 (see Outcome Measure 1), UPDRS-III (see Outcome Measure 10), UPDRS-IV (see description below), and Global NMSS (see Outcome Measure 11). The UPDRS-IV contains 11 items, each scored in a Likert scale from 0 (normal) to 4 (severe); or a 2-point scale (yes/no format), with 1 point for "yes" and 0 for "no." The global score was calculated summing the score of each item, ranging from 0 to 23, where higher scores are associated with more disability.

    Time frame: Month 6 (±15 days)

07

Results

Posted Jan 30, 2019

Participant flow

Participant flow — Overall Study
MilestoneAll Participants
Started59
Completed53
Not completed6
Withdrew: Lack of efficacy3
Withdrew: Very narrow therapeutic margin1
Withdrew: Withdrawal by subject1
Withdrew: Death1

Outcome measures

PrimaryChange From Baseline in Parkinson's Disease Questionnaire-39 Item (PDQ-39) Global Score at Month 6

The PDQ-39 contains 39 items: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (score 0 to 4 on a Likert scale). The global score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire-39 Item (PDQ-39) Global Score at Month 6
units on a scaleAll Participants
Change From Baseline in Parkinson's Disease Questionnaire-39 Item (PDQ-39) Global Score at Month 6-12.81 ± 14.65
Statistical analysis
  • All Participants · t-test · p = < 0.0001
PrimaryChange From Baseline in PDQ-39 Mobility Domain Score at Month 6

The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The mobility domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in PDQ-39 Mobility Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in PDQ-39 Mobility Domain Score at Month 6-16.92 ± 24.90
Statistical analysis
  • All Participants · t-test · p = < 0.0001
PrimaryChange From Baseline in PDQ-39 Activities of Daily Living Domain Score at Month 6

The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The activities of daily living domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in PDQ-39 Activities of Daily Living Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in PDQ-39 Activities of Daily Living Domain Score at Month 6-18.43 ± 23.52
Statistical analysis
  • All Participants · t-test · p = < 0.0001
PrimaryChange From Baseline in PDQ-39 Emotional Well-Being Domain Score at Month 6

The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The emotional well-being domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in PDQ-39 Emotional Well-Being Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in PDQ-39 Emotional Well-Being Domain Score at Month 6-13.06 ± 19.56
Statistical analysis
  • All Participants · t-test · p = < 0.0001
PrimaryChange From Baseline in PDQ-39 Stigma Domain Score at Month 6

The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The stigma domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in PDQ-39 Stigma Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in PDQ-39 Stigma Domain Score at Month 6-6.85 ± 20.53
Statistical analysis
  • All Participants · t-test · p = 0.0328
PrimaryChange From Baseline in PDQ-39 Social Support Domain Score at Month 6

The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The social support domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in PDQ-39 Social Support Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in PDQ-39 Social Support Domain Score at Month 6-2.08 ± 15.56
Statistical analysis
  • All Participants · t-test · p = 0.4183
PrimaryChange From Baseline in PDQ-39 Cognition Domain Score at Month 6

The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The cognition domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in PDQ-39 Cognition Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in PDQ-39 Cognition Domain Score at Month 6-13.22 ± 19.94
Statistical analysis
  • All Participants · t-test · p = < 0.0001
PrimaryChange From Baseline in PDQ-39 Communication Domain Score at Month 6

The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The communication domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in PDQ-39 Communication Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in PDQ-39 Communication Domain Score at Month 6-9.13 ± 17.17
Statistical analysis
  • All Participants · t-test · p = 0.0003
PrimaryChange From Baseline in PDQ-39 Bodily Discomfort Domain Score at Month 6

The PDQ-39 contains 39 items grouped in 8 domains: mobility (items 1-10), activities of daily living (items 11-16), emotional well-being (items 17-22), stigma (items 23-26), social support (items 27-29), cognitions (items 30-33), communication (items 34-36), and bodily discomfort (items 37-39). Participants are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never, occasionally, sometimes, often, always or cannot do at all, scoring 0, 1, 2, 3 or 4, respectively. The bodily discomfort domain score was calculated by expressing summed item scores as a percentage score ranging between 0 and 100. The lower scores indicate a better perceived health status and higher scores are associated with more health problems.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in PDQ-39 Bodily Discomfort Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in PDQ-39 Bodily Discomfort Domain Score at Month 6-9.13 ± 24.93
Statistical analysis
  • All Participants · t-test · p = 0.0109
SecondaryChange From Baseline in Unified Parkinson's Disease Rating Scale Part III (UPDRS-III): Motor Examination at Month 6

The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS-III was used in ON state. The motor examination contains 27 items. Each item is scored in a Likert scale from 0 to 4. The UPDRS-III score was calculated summing the score of each item, ranging from 0 to 108, with higher score indicating more impairment.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in Unified Parkinson's Disease Rating Scale Part III (UPDRS-III): Motor Examination at Month 6
units on a scaleAll Participants
Change From Baseline in Unified Parkinson's Disease Rating Scale Part III (UPDRS-III): Motor Examination at Month 6-6.51 ± 11.83
Statistical analysis
  • All Participants · t-test · p = 0.0002
SecondaryChange From Baseline in the Non-Motor Symptom Scale (NMSS) Global Score at Month 6

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The global score was calculated summing the score of each item (severity x frequency), ranging from 0 to 360, with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Non-Motor Symptom Scale (NMSS) Global Score at Month 6
units on a scaleAll Participants
Change From Baseline in the Non-Motor Symptom Scale (NMSS) Global Score at Month 6-35.75 ± 31.12
Statistical analysis
  • All Participants · t-test · p = < 0.0001
SecondaryChange From Baseline in NMSS Cardiovascular Domain Score at Month 6

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The cardiovascular domain score ranges from 0 to 24 with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in NMSS Cardiovascular Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in NMSS Cardiovascular Domain Score at Month 6-1.81 ± 3.51
Statistical analysis
  • All Participants · signed-rank test · p = 0.0002
SecondaryChange From Baseline in NMSS Sleep/Fatigue Domain Score at Month 6

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The sleep/fatigue domain score ranges from 0 to 48 with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in NMSS Sleep/Fatigue Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in NMSS Sleep/Fatigue Domain Score at Month 6-8.73 ± 7.77
Statistical analysis
  • All Participants · t-test · p = < 0.0001
SecondaryChange From Baseline in NMSS Mood/Cognition Domain Score at Month 6

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The mood/cognition domain score ranges from 0 to 72 with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in NMSS Mood/Cognition Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in NMSS Mood/Cognition Domain Score at Month 6-5.83 ± 13.84
Statistical analysis
  • All Participants · t-test · p = 0.0038
SecondaryChange From Baseline in NMSS Perceptual Problems/Hallucinations Domain Score at Month 6

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The perceptual problems/hallucinations domain score ranges from 0 to 36 with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in NMSS Perceptual Problems/Hallucinations Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in NMSS Perceptual Problems/Hallucinations Domain Score at Month 62.12 ± 5.03
Statistical analysis
  • All Participants · signed-rank test · p = < 0.0001
SecondaryChange From Baseline in NMSS Attention/Memory Domain Score at Month 6

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The attention/memory domain score ranges from 0 to 36 with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in NMSS Attention/Memory Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in NMSS Attention/Memory Domain Score at Month 6-1.12 ± 6.21
Statistical analysis
  • All Participants · signed-rank test · p = 0.0274
SecondaryChange From Baseline in NMSS Gastrointestinal Tract Domain Score at Month 6

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The gastrointestinal tract domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in NMSS Gastrointestinal Tract Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in NMSS Gastrointestinal Tract Domain Score at Month 6-3.58 ± 5.08
Statistical analysis
  • All Participants · signed-rank test · p = < 0.0001
SecondaryChange From Baseline in NMSS Urinary Domain Score at Month 6

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The urinary domain score ranges from 0 to 36 with a lower score indicating fewer symptoms.A negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in NMSS Urinary Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in NMSS Urinary Domain Score at Month 6-5.19 ± 10.24
Statistical analysis
  • All Participants · t-test · p = 0.0006
SecondaryChange From Baseline in NMSS Sexual Function Domain Score at Month 6

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The sexual function domain score ranges from 0 to 24 with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in NMSS Sexual Function Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in NMSS Sexual Function Domain Score at Month 6-2.94 ± 6.80
Statistical analysis
  • All Participants · signed-rank test · p = 0.0010
SecondaryChange From Baseline in NMSS Miscellaneous Domain Score at Month 6

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular including falls (items 1-2), sleep/fatigue (items 3-6), mood/cognition (items 7-12), perceptual problems/hallucinations (items 13-15), attention/memory (items 16-18), gastrointestinal tract (items 19-21), urinary (items 22-24), sexual function (items 25-26), and miscellaneous (pain, taste/smell, weight change, excessive sweating; items 27-30). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). The miscellaneous domain score ranges from 0 to 48 with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in NMSS Miscellaneous Domain Score at Month 6
units on a scaleAll Participants
Change From Baseline in NMSS Miscellaneous Domain Score at Month 6-4.47 ± 8.00
Statistical analysis
  • All Participants · t-test · p = 0.0002
SecondaryChange From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Mean Global Score at Month 6

The Norris/Bond-Lader VAS measures emotional well-being status with a 16-item visual analogue mood rating scale. The VAS consisted of 16 visual analogue items each representing opposite extremes of mood, with the following labels at each end: alert/drowsy, calm/excited, strong/weak, muzzy/clear-headed, well-coordinated/clumsy, lethargic/energetic, contented/dreamy, incompetent/proficient, happy/sad, antagonistic/amicable, interested/bored, withdrawn/gregarious. These scales loaded on 3 domains (alert, strong, clear-headed, well-coordinated, energetic, quick-witted, attentive, proficient, interested); (contented, tranquil, happy, amicable, gregarious); (calm, relaxed). For each individual scale, a line was drawn between each mood state and its opposite and participants rated their current mood by placing a vertical mark on the line. Scores (global, and for each domain) ranged from 0 to 100, with lower scores indicating more positive mood.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Mean Global Score at Month 6
units on a scaleAll Participants
Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Mean Global Score at Month 6-6.63 ± 21.15
Statistical analysis
  • All Participants · t-test · p = 0.0297
SecondaryChange From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Alertness/Sedation Sub-Scale Score at Month 6

The Norris/Bond-Lader VAS measures emotional well-being status with a 16-item visual analogue mood rating scale. The VAS consisted of 16 visual analogue items each representing opposite extremes of mood, with the following labels at each end: alert/drowsy, calm/excited, strong/weak, muzzy/clear-headed, well-coordinated/clumsy, lethargic/energetic, contented/dreamy, incompetent/proficient, happy/sad, antagonistic/amicable, interested/bored, withdrawn/gregarious. These scales loaded on 3 domains (alert, strong, clear-headed, well-coordinated, energetic, quick-witted, attentive, proficient, interested); (contented, tranquil, happy, amicable, gregarious); (calm, relaxed). For each individual scale, a line was drawn between each mood state and its opposite and participants rated their current mood by placing a vertical mark on the line. Scores (global, and for each domain) ranged from 0 to 100, with lower scores indicating more positive mood.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Alertness/Sedation Sub-Scale Score at Month 6
units on a scaleAll Participants
Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Alertness/Sedation Sub-Scale Score at Month 6-7.38 ± 23.27
Statistical analysis
  • All Participants · t-test · p = 0.0279
SecondaryChange From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Contented/Discontented Sub-Scale Score at Month 6

The Norris/Bond-Lader VAS measures emotional well-being status with a 16-item visual analogue mood rating scale. The VAS consisted of 16 visual analogue items each representing opposite extremes of mood, with the following labels at each end: alert/drowsy, calm/excited, strong/weak, muzzy/clear-headed, well-coordinated/clumsy, lethargic/energetic, contented/dreamy, incompetent/proficient, happy/sad, antagonistic/amicable, interested/bored, withdrawn/gregarious. These scales loaded on 3 domains (alert, strong, clear-headed, well-coordinated, energetic, quick-witted, attentive, proficient, interested); (contented, tranquil, happy, amicable, gregarious); (calm, relaxed). For each individual scale, a line was drawn between each mood state and its opposite and participants rated their current mood by placing a vertical mark on the line. Scores (global, and for each domain) ranged from 0 to 100, with lower scores indicating more positive mood.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Contented/Discontented Sub-Scale Score at Month 6
units on a scaleAll Participants
Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Contented/Discontented Sub-Scale Score at Month 6-3.37 ± 21.92
Statistical analysis
  • All Participants · t-test · p = 0.2777
SecondaryChange From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Calmness/Relaxation Sub-Scale Score at Month 6

The Norris/Bond-Lader VAS measures emotional well-being status with a 16-item visual analogue mood rating scale. The VAS consisted of 16 visual analogue items each representing opposite extremes of mood, with the following labels at each end: alert/drowsy, calm/excited, strong/weak, muzzy/clear-headed, well-coordinated/clumsy, lethargic/energetic, contented/dreamy, incompetent/proficient, happy/sad, antagonistic/amicable, interested/bored, withdrawn/gregarious. These scales loaded on 3 domains (alert, strong, clear-headed, well-coordinated, energetic, quick-witted, attentive, proficient, interested); (contented, tranquil, happy, amicable, gregarious); (calm, relaxed). For each individual scale, a line was drawn between each mood state and its opposite and participants rated their current mood by placing a vertical mark on the line. Scores (global, and for each domain) ranged from 0 to 100, with lower scores indicating more positive mood.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Calmness/Relaxation Sub-Scale Score at Month 6
units on a scaleAll Participants
Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Calmness/Relaxation Sub-Scale Score at Month 6-11.58 ± 27.94
Statistical analysis
  • All Participants · t-test · p = 0.0047
SecondaryChange From Baseline in Parkinson Fatigue Scale (PFS-16) at Month 6

The PFS-16 comprises 16 items with five polytomous response categories (strongly disagree, disagree, do not agree or disagree, agree, and strongly agree). Responses were scored from 0 (strongly disagree) to 4 (strongly agree), yielding a summed total score ranging from 0 (no fatigue) to 64 (most severe fatigue). The cut-point of ≥ 3.30 was used to identified those perceiving fatigue to be a problem.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson Fatigue Scale (PFS-16) at Month 6
units on a scaleAll Participants
Change From Baseline in Parkinson Fatigue Scale (PFS-16) at Month 6-0.56 ± 1.01
Statistical analysis
  • All Participants · t-test · p = 0.0003
SecondaryChange From Baseline in the Score of the Apathy Scale (AS) to Month 6

The AS is an inventory of 14 questions that assess cognitive and behavioral symptoms of emotional apathy. Each is rated from 0 to 3 on a Likert scale. The total scores for AS ranges from 0 (no apathy) to 42 (most apathetic). AS scores ≥ 14 were considered apathetic.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Score of the Apathy Scale (AS) to Month 6
units on a scaleAll Participants
Change From Baseline in the Score of the Apathy Scale (AS) to Month 6-0.52 ± 6.86
Statistical analysis
  • All Participants · t-test · p = <0.5877
SecondaryChange From Baseline in Beck Depression Inventory, Second Edition (BDI-II) at Month 6

The BDI-II is a 21-item self-report multiple-choice inventory. Items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63. Raw scores from 0-13 indicates minimal depression, 14-19 indicates mild depression, 20-28 indicates moderate depression, and 29-63 indicates severe depression.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in Beck Depression Inventory, Second Edition (BDI-II) at Month 6
units on a scaleAll Participants
Change From Baseline in Beck Depression Inventory, Second Edition (BDI-II) at Month 6-5.15 ± 9.39
Statistical analysis
  • All Participants · t-test · p = 0.0002
SecondaryChange From Baseline in Beck Anxiety Inventory (BAI) at Month 6

The BAI is a 21-item self-report multiple-choice inventory. Items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63. Raw scores from 0-7 indicates minimal anxiety, 8-15 indicates mild anxiety, 16-25 indicates moderate anxiety, and 25-63 indicates severe anxiety.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in Beck Anxiety Inventory (BAI) at Month 6
units on a scaleAll Participants
Change From Baseline in Beck Anxiety Inventory (BAI) at Month 6-6.21 ± 9.57
Statistical analysis
  • All Participants · t-test · p = <0.0001
SecondaryChange From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Composite Score at Month 6

The SATMED-Q is a 17-item questionnaire. Items are grouped in 6 domains: undesirable side effects (items 1-3), treatment effectiveness (items 4-6), convenience of use (items 7-9), impact on daily living activities (items 10-12), medical care (items 13-14), and global satisfaction (items 15-17). Items are rated on a 5-point scale ranging from 0 to 4. Summing up the direct scores of the items yields a total composite score ranging between 0 and 68, which was transformed to a minimum of 0 (most satisfied) and a maximum of 100 (least satisfied).

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Composite Score at Month 6
units on a scaleAll Participants
Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Composite Score at Month 616.15 ± 16.80
Statistical analysis
  • All Participants · t-test · p = < 0.0001
SecondaryChange From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Undesirable Side Effects at Month 6

The SATMED-Q is a 17-item questionnaire. Items are grouped in 6 domains: undesirable side effects (items 1-3), treatment effectiveness (items 4-6), convenience of use (items 7-9), impact on daily living activities (items 10-12), medical care (items 13-14), and global satisfaction (items 15-17). Items are rated on a 4-point scale ranging from 0 to 4. Summing up the direct scores of the items yields a total undesirable side effects score ranging between 0 and 12, which was transformed to a minimum of 0 (most satisfied) and a maximum of 100 (least satisfied).

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Undesirable Side Effects at Month 6
units on a scaleAll Participants
Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Undesirable Side Effects at Month 6-25.00 ± 39.05
Statistical analysis
  • All Participants · signed-rank test · p = < 0.0001
SecondaryChange From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Treatment Effectiveness at Month 6

The SATMED-Q is a 17-item questionnaire. Items are grouped in 6 domains: undesirable side effects (items 1-3), treatment effectiveness (items 4-6), convenience of use (items 7-9), impact on daily living activities (items 10-12), medical care (items 13-14), and global satisfaction (items 15-17). Items are rated on a 4-point scale ranging from 0 to 4. Summing up the direct scores of the items yields a total treatment effectiveness score ranging between 0 and 12, which was transformed to a minimum of 0 (most satisfied) and a maximum of 100 (least satisfied).

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Treatment Effectiveness at Month 6
units on a scaleAll Participants
Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Treatment Effectiveness at Month 630.39 ± 31.57
Statistical analysis
  • All Participants · t-test · p = < 0.0001
SecondaryChange From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Convenience of Use at Month 6

The SATMED-Q is a 17-item questionnaire. Items are grouped in 6 domains: undesirable side effects (items 1-3), treatment effectiveness (items 4-6), convenience of use (items 7-9), impact on daily living activities (items 10-12), medical care (items 13-14), and global satisfaction (items 15-17). Items are rated on a 4-point scale ranging from 0 to 4. Summing up the direct scores of the items yields a total convenience of use score ranging between 0 and 12, which was transformed to a minimum of 0 (most satisfied) and a maximum of 100 (least satisfied).

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Convenience of Use at Month 6
units on a scaleAll Participants
Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Convenience of Use at Month 619.77 ± 33.83
Statistical analysis
  • All Participants · t-test · p = 0.0001
SecondaryChange From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Impact on Daily Living Activities at Month 6

The SATMED-Q is a 17-item questionnaire. Items are grouped in 6 domains: undesirable side effects (items 1-3), treatment effectiveness (items 4-6), convenience of use (items 7-9), impact on daily living activities (items 10-12), medical care (items 13-14), and global satisfaction (items 15-17). Items are rated on a 4-point scale ranging from 0 to 4. Summing up the direct scores of the items yields a total impact on daily living activities score ranging between 0 and 12, which was transformed to a minimum of 0 (most satisfied) and a maximum of 100 (least satisfied).

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Impact on Daily Living Activities at Month 6
units on a scaleAll Participants
Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Impact on Daily Living Activities at Month 618.75 ± 30.78
Statistical analysis
  • All Participants · signed-rank test · p = < 0.0001
SecondaryChange From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Medical Care at Month 6

The SATMED-Q is a 17-item questionnaire. Items are grouped in 6 domains: undesirable side effects (items 1-3), treatment effectiveness (items 4-6), convenience of use (items 7-9), impact on daily living activities (items 10-12), medical care (items 13-14), and global satisfaction (items 15-17). Items are rated on a 4-point scale ranging from 0 to 4. Summing up the direct scores of the items yields a total medical care score ranging between 0 and 8, which was transformed to a minimum of 0 (most satisfied) and a maximum of 100 (least satisfied).

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Medical Care at Month 6
units on a scaleAll Participants
Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Medical Care at Month 64.09 ± 22.51
Statistical analysis
  • All Participants · signed-rank test · p = 0.2428
SecondaryChange From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Global Satisfaction at Month 6

The SATMED-Q is a 17-item questionnaire. Items are grouped in 6 domains: undesirable side effects (items 1-3), treatment effectiveness (items 4-6), convenience of use (items 7-9), impact on daily living activities (items 10-12), medical care (items 13-14), and global satisfaction (items 15-17). Items are rated on a 4-point scale ranging from 0 to 4. Summing up the direct scores of the items yields a total global satisfaction score ranging between 0 and 12, which was transformed to a minimum of 0 (most satisfied) and a maximum of 100 (least satisfied).

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Global Satisfaction at Month 6
units on a scaleAll Participants
Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Global Satisfaction at Month 644.44 ± 32.00
Statistical analysis
  • All Participants · t-test · p = 0.0687
SecondaryChange From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Composite Score at Month 6

The SQLC is designed to both qualitatively and quantitatively evaluate the impact of a patient's disease on the caregiver's quality of life. The SQLC questionnaire consists of 16 questions that evaluate 3 domains: professional activities (questions 1-4), social and leisure activities (questions 5-9), and caregiving responsibilities (questions 10-16). Composite scores range from 0 to 149, with higher scores indicating higher quality of life.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Composite Score at Month 6
units on a scaleAll Participants
Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Composite Score at Month 63.21 ± 21.57
Statistical analysis
  • All Participants · t-test · p = 0.3126
SecondaryChange From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Professional Activities at Month 6

The SQLC is designed to both qualitatively and quantitatively evaluate the impact of a patient's disease on the caregiver's quality of life. The SQLC questionnaire consists of 16 questions that evaluate 3 domains: professional activities (questions 1-4), social and leisure activities (questions 5-9), and caregiving responsibilities (questions 10-16). Professional activities scores range from 0 to 38, with higher scores indicating higher quality of life.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Professional Activities at Month 6
units on a scaleAll Participants
Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Professional Activities at Month 62.55 ± 12.06
Statistical analysis
  • All Participants · t-test · p = 0.1533
SecondaryChange From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Social and Leisure Activities at Month 6

The SQLC is designed to both qualitatively and quantitatively evaluate the impact of a patient's disease on the caregiver's quality of life. The SQLC questionnaire consists of 16 questions that evaluate 3 domains: professional activities (questions 1-4), social and leisure activities (questions 5-9), and caregiving responsibilities (questions 10-16). Social and leisure activities scores range from 0 to 58, with higher scores indicating higher quality of life.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Social and Leisure Activities at Month 6
units on a scaleAll Participants
Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Social and Leisure Activities at Month 6-0.21 ± 6.18
Statistical analysis
  • All Participants · t-test · p = 0.8145
SecondaryChange From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Caregiving Responsibilities at Month 6

The SQLC is designed to both qualitatively and quantitatively evaluate the impact of a patient's disease on the caregiver's quality of life. The SQLC questionnaire consists of 16 questions that evaluate 3 domains: professional activities (questions 1-4), social and leisure activities (questions 5-9), and caregiving responsibilities (questions 10-16). Caregiving responsibilities scores range from 0 to 53, with higher scores indicating higher quality of life.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Caregiving Responsibilities at Month 6
units on a scaleAll Participants
Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Caregiving Responsibilities at Month 60.87 ± 7.11
Statistical analysis
  • All Participants · t-test · p = 0.4048
SecondaryChange From Baseline in Zarit Burden Interview (ZBI) at Month 6

The ZBI is a 22-item questionnaire in which caregivers must evaluate the level of agreement on a 5-point Likert scale from 0 to 4. The total score is obtained by the sum of the scores of the items. This total score represents a level of caregiver burden, with a range of 0 indicating no burden to 88 indicating completely overloaded.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in Zarit Burden Interview (ZBI) at Month 6
units on a scaleAll Participants
Change From Baseline in Zarit Burden Interview (ZBI) at Month 6-0.32 ± 10.26
Statistical analysis
  • All Participants · t-test · p = 0.8321
SecondaryChange From Baseline in the Caregiver Stress Index (CSI) at Month 6

The CSI is a 13-item questionnaire based on identified common stressors. Answers are in yes/no format. Scoring is 1 point for each "yes" and 0 for each "no". The total score is obtained by the sum of the scores of the items. Minimum score is 0 (no stress) and maximum score is 13 (most stress). A score ≥ 7 indicates a high level of stress.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in the Caregiver Stress Index (CSI) at Month 6
units on a scaleAll Participants
Change From Baseline in the Caregiver Stress Index (CSI) at Month 6-0.55 ± 2.58
Statistical analysis
  • All Participants · signed-rank test · p = 0.1945
SecondaryChange From Baseline in Goldberg Anxiety and Depression Score (GADS): Depression Sub-Scale for Caregivers at Month 6

The GADS is an 18-item self-report symptom inventory made up of two sub-scales, one for the detection of anxiety and another one for the detection of depression. Both sub-scales are composed of 9 questions. Answers are in yes/no format. Scoring is 1 point for each "yes" and 0 for each "no", with a total sub-scale score of 0 (no anxiety/depression) to 9 (worst anxiety/depression). In the Spanish validation of GADS, the cutoff point to consider probable anxiety disorder is 4 and 2 for probable depression.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in Goldberg Anxiety and Depression Score (GADS): Depression Sub-Scale for Caregivers at Month 6
units on a scaleAll Participants
Change From Baseline in Goldberg Anxiety and Depression Score (GADS): Depression Sub-Scale for Caregivers at Month 60.20 ± 2.35
Statistical analysis
  • All Participants · t-test · p = 0.7937
SecondaryChange From Baseline in Goldberg Anxiety and Depression Score (GADS): Anxiety Sub-Scale for Caregivers at Month 6

The GADS is an 18-item self-report symptom inventory made up of two sub-scales, one for the detection of anxiety and another one for the detection of depression. Both sub-scales are composed of 9 questions. Answers are in yes/no format. Scoring is 1 point for each "yes" and 0 for each "no", with a total sub-scale score of 0 (no anxiety/depression) to 9 (worst anxiety/depression). In the Spanish validation of GADS, the cutoff point to consider probable anxiety disorder is 4 and 2 for probable depression.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · units on a scale
Change From Baseline in Goldberg Anxiety and Depression Score (GADS): Anxiety Sub-Scale for Caregivers at Month 6
units on a scaleAll Participants
Change From Baseline in Goldberg Anxiety and Depression Score (GADS): Anxiety Sub-Scale for Caregivers at Month 6-1.10 ± 0.99
Statistical analysis
  • All Participants · signed-rank test · p = 0.0234
SecondaryChange From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) at Month 6

Absenteeism, presented as the mean percentage of work time missed due to caregiving (as reported on the WPAI), and calculated as: 100\*number of hours of work missed due to caregiving / (number of hours of work missed due to caregiving + number of hours worked). WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · percentage of work time missed
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) at Month 6
percentage of work time missedAll Participants
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) at Month 6-7.56 ± 40.68
Statistical analysis
  • All Participants · t-test · p = 0.5922
SecondaryChange From Baseline in WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Caregiving (Presenteeism)

Presenteeism (the extent to which caregiving decreased productivity) is presented as the mean percentage of impairment while working due to caregiving, and calculated as: 100\*scale value of question 5 on the WPAI (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · percentage of work impairment
Change From Baseline in WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Caregiving (Presenteeism)
percentage of work impairmentAll Participants
Change From Baseline in WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Caregiving (Presenteeism)0.00 ± 18.03
Statistical analysis
  • All Participants · t-test · p = 1.000
SecondaryChange From Baseline in WPAI Questionnaire: Mean Percentage of Overall Work Productivity Impairment (OWPI) Due to Caregiving

The mean percentage of OWPI due to caregiving (based on the WPAI questionnaire) is presented, calculated as: Absenteeism (%) + extent to which caregiving decreased productivity (%)\* \[number of hours worked / (number of hours of work missed due to caregiving + number of hours worked)\]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · percentage of overall work impairment
Change From Baseline in WPAI Questionnaire: Mean Percentage of Overall Work Productivity Impairment (OWPI) Due to Caregiving
percentage of overall work impairmentAll Participants
Change From Baseline in WPAI Questionnaire: Mean Percentage of Overall Work Productivity Impairment (OWPI) Due to Caregiving-6.69 ± 42.34
Statistical analysis
  • All Participants · t-test · p = 0.6481
SecondaryChange From Baseline in WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Caregiving

Activity impairment due to caregiving (the extent to which caregiving affected the ability to perform usual daily activities) is presented as the mean percentage of activity impairment, calculated as 100\*scale value of WPAI question 6 (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity/activity and 100% representing complete impact on productivity/activity.

Time frame:
Baseline, Month 6 (±15 days)
Reported as:
Mean · percentage of activity impairment
Change From Baseline in WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Caregiving
percentage of activity impairmentAll Participants
Change From Baseline in WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Caregiving-3.33 ± 22.91
Statistical analysis
  • All Participants · t-test · p = 0.6741
SecondaryCorrelation Between Participants' Quality of Life (PDQ-39) and Different Questionnaires at Baseline

Spearman correlation statistics were calculated for the quality of life of the participants (Global PDQ-39, see Outcome Measure 1) and the following scales: UPDRS-III (see Outcome Measure 10), UPDRS-IV (see description below), NMSS (see Outcome Measure 11), BAI (see Outcome Measure 28), BDI-III (see Outcome Measure 27), AS (see Outcome Measure 26), PFS (see Outcome Measure 25), Norris Bond-Lader (NBL) Alertness-Sedation (A-S; see Outcome Measure 22), NBL Contented-Discontented (C-D; see Outcome Measure 23), NBL Calm-Relaxed (C-R; see Outcome Measure 24), ZBI (see Outcome Measure 40), GADS-Anxiety (see Outcome Measure 43), and GADS-Depression (see Outcome Measure 42). The UPDRS-IV contains 11 items, each scored in a Likert scale from 0 (normal) to 4 (severe); or a 2-point scale (yes/no format), with 1 point for "yes" and 0 for "no." The global score was calculated summing the score of each item, ranging from 0 to 23, where higher scores are associated with more disability.

Time frame:
Baseline
Reported as:
Number · correlation coefficient
Correlation Between Participants' Quality of Life (PDQ-39) and Different Questionnaires at Baseline
correlation coefficientAll Participants
PDQ-39 with UPDRS-III0.27148
PDQ-39 with UPDRS-IV0.07346
PDQ-39 with NMSS0.20994
PDQ-39 with BAI0.28271
PDQ-39 with BDI-II0.46174
PDQ-39 with AS0.08846
PDQ-39 with PFS0.33361
PDQ-39 with NBL A-S0.22085
PDQ-39 with NBL C-D0.35742
PDQ-39 with NBL C-R0.00011
PDQ-39 with ZBI-0.35125
PDQ-39 with GADS-Anxiety0.21311
PDQ-39 with GADS-Depression0.51846
Statistical analysis
  • All Participants · Fisher's z Transformation · p = 0.0389 · Fisher's z: 0.27846 · 95% CI 0.014175 to 0.495059
  • All Participants · Fisher's z Transformation · p = 0.5852 · Fisher's z: 0.07359 · 95% CI -0.188409 to 0.325580
  • All Participants · Fisher's z Transformation · p = 0.1140 · Fisher's z: 0.21311 · 95% CI -0.051127 to 0.444152
  • All Participants · Fisher's z Transformation · p = 0.0311 · Fisher's z: 0.29062 · 95% CI 0.026334 to 0.504186
  • All Participants · Fisher's z Transformation · p = 0.0002 · Fisher's z: 0.49952 · 95% CI 0.230995 to 0.643312
  • All Participants · Fisher's z Transformation · p = 0.5146 · Fisher's z: 0.08869 · 95% CI -0.176169 to 0.341163
  • All Participants · Fisher's z Transformation · p = 0.0108 · Fisher's z: 0.34688 · 95% CI 0.079996 to 0.546657
  • All Participants · Fisher's z Transformation · p = 0.0989 · Fisher's z: 0.22455 · 95% CI -0.042139 to 0.455224
  • All Participants · Fisher's z Transformation · p = 0.0060 · Fisher's z: 0.35742 · 95% CI 0.106797 to 0.565335
  • All Participants · Fisher's z Transformation · p = 0.9993 · Fisher's z: 0.00011 · 95% CI -0.260462 to 0.260673
  • All Participants · Fisher's z Transformation · p = 0.0088 · Fisher's z: -0.36687 · 95% CI -0.565795 to -0.092154
  • All Participants · Fisher's z Transformation · p = 0.1222 · Fisher's z: 0.21643 · 95% CI -0.057959 to 0.454911
  • All Participants · Fisher's z Transformation · p = 0.0041 · Fisher's z: 0.57423 · 95% CI 0.180247 to 0.747040
SecondaryCorrelation Between Participants' Quality of Life (PDQ-39) and Different Questionnaires at Month 6

Spearman correlation statistics were calculated for the quality of life of the participants (Global PDQ-39, see Outcome Measure 1) and the following scales: UPDRS-III (see Outcome Measure 10), UPDRS-IV (see description below), NMSS (see Outcome Measure 11), BAI (see Outcome Measure 28), BDI-III (see Outcome Measure 27), AS (see Outcome Measure 26), PFS (see Outcome Measure 25), Norris Bond-Lader (NBL) Alertness-Sedation (A-S; see Outcome Measure 22), NBL Contented-Discontented (C-D; see Outcome Measure 23), NBL Calm-Relaxed (C-R; see Outcome Measure 24), ZBI (see Outcome Measure 40), GADS-Anxiety (see Outcome Measure 43), and GADS-Depression (see Outcome Measure 42). The UPDRS-IV contains 11 items, each scored in a Likert scale from 0 (normal) to 4 (severe); or a 2-point scale (yes/no format), with 1 point for "yes" and 0 for "no." The global score was calculated summing the score of each item, ranging from 0 to 23, where higher scores are associated with more disability.

Time frame:
Month 6 (±15 days)
Reported as:
Number · correlation coefficient
Correlation Between Participants' Quality of Life (PDQ-39) and Different Questionnaires at Month 6
correlation coefficientAll Participants
PDQ-39 with UPDRS-III0.30902
PDQ-39 with UPDRS-IV0.35220
PDQ-39 with NMSS0.36814
PDQ-39 with BAI0.60620
PDQ-39 with BDI-II0.56325
PDQ-39 with AS0.23657
PDQ-39 with PFS0.58572
PDQ-39 with NBL A-S0.54139
PDQ-39 with NBL C-D0.54140
PDQ-39 with NBL C-R0.38968
PDQ-39 with ZBI-0.32445
PDQ-39 with GADS-Anxiety0.56873
PDQ-39 with GADS-Depression0.10855
Statistical analysis
  • All Participants · Fisher's z Transformation · p = 0.0239 · Fisher's z: 0.31946 · 95% CI 0.042257 to 0.534657
  • All Participants · Fisher's z Transformation · p = 0.0093 · Fisher's z: 0.36796 · 95% CI 0.090528 to 0.568388
  • All Participants · Fisher's z Transformation · p = 0.0069 · Fisher's z: 0.38627 · 95% CI 0.105875 to 0.582517
  • All Participants · Fisher's z Transformation · p = < 0.0001 · Fisher's z: 0.70289 · 95% CI 0.401730 to 0.753097
  • All Participants · Fisher's z Transformation · p = <0.0001 · Fisher's z: 0.63758 · 95% CI 0.345567 to 0.723410
  • All Participants · Fisher's z Transformation · p = 0.0882 · Fisher's z: 0.24114 · 95% CI -0.036024 to 0.476404
  • All Participants · Fisher's z Transformation · p = < 0.0001 · Fisher's z: 0.67113 · 95% CI 0.374757 to 0.739016
  • All Participants · Fisher's z Transformation · p = < 0.0001 · Fisher's z: 0.60612 · 95% CI 0.317572 to 0.708072
  • All Participants · Fisher's z Transformation · p = < 0.0001 · Fisher's z: 0.60613 · 95% CI 0.317580 to 0.708076
  • All Participants · Fisher's z Transformation · p = 0.0036 · Fisher's z: 0.41143 · 95% CI 0.133445 to 0.597087
  • All Participants · Fisher's z Transformation · p = 0.0239 · Fisher's z: -0.33661 · 95% CI -0.557217 to -0.044411
  • All Participants · Fisher's z Transformation · p = < 0.0001 · Fisher's z: 0.64565 · 95% CI 0.339454 to 0.734221
  • All Participants · Fisher's z Transformation · p = 0.7058 · Fisher's z: 0.10898 · 95% CI -0.427482 to 0.588111
SecondaryCorrelation Between Caregivers' Quality of Life (SQLC) and Different Questionnaires at Baseline

Spearman correlation statistics were calculated for the quality of life of the caregivers (Global SQLC, see Outcome Measure ) and the following scales: ZBI (see Outcome Measure 40), GADS-Anxiety (see Outcome Measure 43), and GADS-Depression (see Outcome Measure 42), NBL A-S (see Outcome Measure 22), NBL C-D (see Outcome Measure 23), NBL C-R (see Outcome Measure 24), Global PDQ-39 (see Outcome Measure 1), UPDRS-III (see Outcome Measure 10), UPDRS-IV (see description below), and Global NMSS (see Outcome Measure 11). The UPDRS-IV contains 11 items, each scored in a Likert scale from 0 (normal) to 4 (severe); or a 2-point scale (yes/no format), with 1 point for "yes" and 0 for "no." The global score was calculated summing the score of each item, ranging from 0 to 23, where higher scores are associated with more disability.

Time frame:
Baseline
Reported as:
Number · correlation coefficient
Correlation Between Caregivers' Quality of Life (SQLC) and Different Questionnaires at Baseline
correlation coefficientAll Participants
SQLC with ZBI-0.51735
SQLC with GADS-Anxiety-0.16188
SQLC with GADS-Depression-0.44739
SQLC with NBL A-S0.06318
SQLC with NBL C-D0.17492
SQLC with NBL C-R0.28618
SQLC with Global PDQ-39-0.35125
SQLC with UPDRS-III-0.13353
SQLC with UPDRS-IV0.17659
SQLC with Global NMSS0.01625
Statistical analysis
  • All Participants · Fisher's z Transformation · p = < 0.0001 · Fisher's z: -0.57271 · 95% CI -0.689585 to -0.289724
  • All Participants · Fisher's z Transformation · p = 0.4142 · Fisher's z: -0.16332 · 95% CI -0.504489 to 0.224771
  • All Participants · Fisher's z Transformation · p = 0.0239 · Fisher's z: -0.48143 · 95% CI -0.715956 to -0.063481
  • All Participants · Fisher's z Transformation · p = 0.6546 · Fisher's z: 0.06326 · 95% CI -0.210715 to 0.327872
  • All Participants · Fisher's z Transformation · p = 0.2114 · Fisher's z: 0.17674 · 95% CI -0.100105 to 0.425116
  • All Participants · Fisher's z Transformation · p = 0.0374 · Fisher's z: 0.29440 · 95% CI 0.017222 to 0.516523
  • All Participants · Fisher's z Transformation · p = 0.0088 · Fisher's z: -0.36687 · 95% CI -0.565795 to -0.092154
  • All Participants · Fisher's z Transformation · p = 0.3374 · Fisher's z: -0.13433 · 95% CI -0.387439 to 0.139207
  • All Participants · Fisher's z Transformation · p = 0.2025 · Fisher's z: 0.17846 · 95% CI -0.095693 to 0.424291
  • All Participants · Fisher's z Transformation · p = 0.9076 · Fisher's z: 0.01625 · 95% CI -0.252613 to 0.282777
SecondaryCorrelation Between Caregivers' Quality of Life (SQLC) and Different Questionnaires at Month 6

Spearman correlation statistics were calculated for the quality of life of the caregivers (Global SQLC, see Outcome Measure ) and the following scales: ZBI (see Outcome Measure 40), GADS-Anxiety (see Outcome Measure 43), and GADS-Depression (see Outcome Measure 42), NBL A-S (see Outcome Measure 22), NBL C-D (see Outcome Measure 23), NBL C-R (see Outcome Measure 24), Global PDQ-39 (see Outcome Measure 1), UPDRS-III (see Outcome Measure 10), UPDRS-IV (see description below), and Global NMSS (see Outcome Measure 11). The UPDRS-IV contains 11 items, each scored in a Likert scale from 0 (normal) to 4 (severe); or a 2-point scale (yes/no format), with 1 point for "yes" and 0 for "no." The global score was calculated summing the score of each item, ranging from 0 to 23, where higher scores are associated with more disability.

Time frame:
Month 6 (±15 days)
Reported as:
Number · correlation coefficient
Correlation Between Caregivers' Quality of Life (SQLC) and Different Questionnaires at Month 6
correlation coefficientAll Participants
SQLC with ZBI-0.63324
SQLC with GADS Anxiety0.17735
SQLC with GADS Depression-0.06976
SQLC with NBL A-S-0.11015
SQLC with NBL C-D0.00326
SQLC with NBL C-R-0.10256
SQLC with Global PDQ-39-0.32445
SQLC with UPDRS-III-0.23226
SQLC with UPDRS-IV-0.12942
SQLC with Global NMSS0.11635
Statistical analysis
  • All Participants · Fisher's z Transformation · p = < 0.0001 · Fisher's z: -0.74680 · 95% CI -0.777482 to -0.425693
  • All Participants · Fisher's z Transformation · p = 0.5347 · Fisher's z: 0.17924 · 95% CI -0.368382 to 0.632178
  • All Participants · Fisher's z Transformation · p = 0.8251 · Fisher's z: -0.06987 · 95% CI -0.597767 to 0.500464
  • All Participants · Fisher's z transformation · p = 0.4581 · Fisher's z: -0.11060 · 95% CI -0.382323 to 0.179601
  • All Participants · Fisher's z Transformation · p = 0.9826 · Fisher's z: 0.00326 · 95% CI -0.281136 to 0.287128
  • All Participants · Fisher's z Transformation · p = 0.4899 · Fisher's z: -0.10293 · 95% CI -0.375749 to 0.187021
  • All Participants · Fisher's z Transformation · p = 0.0239 · Fisher's z: -0.33661 · 95% CI -0.557217 to -0.044411
  • All Participants · Fisher's z Transformation · p = 0.1125 · Fisher's z: -0.23658 · 95% CI -0.484427 to 0.055538
  • All Participants · Fisher's z Transformation · p = 0.3826 · Fisher's z: -0.13015 · 95% CI -0.398887 to 0.160620
  • All Participants · Fisher's z Transformation · p = 0.4382 · Fisher's z: 0.11688 · 95% CI -0.176724 to 0.390468

Adverse events

Collected over Serious adverse events were reported from the time the physician obtained the participant's informed consent until 30 days or 5 half-lives following the intake of the last dose of physician-prescribed treatment. Mean treatment duration was 6.14 ± 1.10 months (median 6.38 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants—18/59 (30.5%)—
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventAll Participants
PneumoperitoneumGastrointestinal disorders4/59
Acute myocardial infarctionCardiac disorders1/59
Angina unstableCardiac disorders1/59
Atrial fibrillationCardiac disorders1/59
Cardiac failureCardiac disorders1/59
Ventricular tachycardiaCardiac disorders1/59
Femoral hernia incarceratedGastrointestinal disorders1/59
Gastroduodenal ulcerGastrointestinal disorders1/59
Ileus paralyticGastrointestinal disorders1/59
InfectionInfections and infestations1/59

Baseline characteristics

participants who received at least 1 dose of LCIG

Age, Continuous
Age, Continuous(years)All Participants
Mean67.93 ± 7.53
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female23
Male36
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Wetmore JB, Arbelo JM, Catalan MJ, Valldeoriola F, Rodriguez-Blazquez C, Martinez-Martin P. Psychometric Properties of the Apathy Scale in Advanced Parkinson's Disease. Parkinsons Dis. 2019 Mar 28;2019:1965394. doi: 10.1155/2019/1965394. eCollection 2019. PubMed 31031906 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02289729
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 13, 2014
Start date
Oct 2014
Primary completion
Nov 2016
Completion
Nov 2016
Results posted
Jan 30, 2019
Last update
Jan 30, 2019

Study contacts

Francesc Valldeoriola, MD
principal investigator · Hospital Clinic of Barcelona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

AbbVie

Start the discussion